KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Depreciation & Amortization (CF) (2016 - 2025)

Idexx Laboratories (IDXX) has 17 years of Depreciation & Amortization (CF) data on record, last reported at $38.7 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 14.88% year-over-year to $38.7 million; the TTM value through Dec 2025 reached $145.2 million, up 11.73%, while the annual FY2025 figure was $145.2 million, 11.73% up from the prior year.
  • Depreciation & Amortization (CF) reached $38.7 million in Q4 2025 per IDXX's latest filing, up from $36.6 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $38.7 million in Q4 2025 and bottomed at $25.1 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $30.3 million, with a median of $28.9 million recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization (CF): dropped 0.95% in 2023, then rose 17.76% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $27.7 million in 2021, then increased by 3.7% to $28.7 million in 2022, then grew by 3.54% to $29.7 million in 2023, then increased by 13.35% to $33.7 million in 2024, then rose by 14.88% to $38.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $38.7 million in Q4 2025, $36.6 million in Q3 2025, and $35.8 million in Q2 2025.